Silence Therapeutics Plc American Depository Share SLN
i
Market dataready · fetched 2026-11-12T02:06:01.454Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-04-16
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T21:27:02.611332556Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-12T02:05:59.614864+00:00
Silence Therapeutics Plc American Depository Share options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 18.32 | 18.0% | 10.0% | |||
| 25Δ | 18.70 | 18.5% | 9.1% | |||
| 30Δ | 19.09 | 19.0% | 8.2% | |||
| 35Δ | 19.47 | 19.4% | 7.3% | |||
| 40Δ | 19.85 | 19.9% | 6.4% | |||
| 45Δ | 19.27 | 8.3% | 1.5% | 20.23 | 20.4% | 5.5% |
| 50Δ | 19.04 | 10.0% | 1.4% | 20.62 | 20.8% | 4.6% |
| 55Δ | 18.81 | 11.6% | 1.4% | 21.00 | 21.3% | 3.7% |
| 60Δ | 18.58 | 13.2% | 1.4% | 21.38 | 21.7% | 2.8% |
| 65Δ | 18.35 | 14.9% | 1.4% | 21.77 | 22.2% | 1.8% |
| 70Δ | 18.11 | 16.5% | 1.4% | 22.15 | 22.7% | 0.9% |
| 75Δ | 17.88 | 18.1% | 1.3% | |||
| 80Δ | 17.65 | 19.8% | 1.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.32
- IV
- 18.0%
- B/E move
- 10.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.70
- IV
- 18.5%
- B/E move
- 9.1%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.09
- IV
- 19.0%
- B/E move
- 8.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.47
- IV
- 19.4%
- B/E move
- 7.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.85
- IV
- 19.9%
- B/E move
- 6.4%
45Δ
- Pseudo strike
- 19.27
- IV
- 8.3%
- B/E move
- 1.5%
- Pseudo strike
- 20.23
- IV
- 20.4%
- B/E move
- 5.5%
50Δ
- Pseudo strike
- 19.04
- IV
- 10.0%
- B/E move
- 1.4%
- Pseudo strike
- 20.62
- IV
- 20.8%
- B/E move
- 4.6%
55Δ
- Pseudo strike
- 18.81
- IV
- 11.6%
- B/E move
- 1.4%
- Pseudo strike
- 21.00
- IV
- 21.3%
- B/E move
- 3.7%
60Δ
- Pseudo strike
- 18.58
- IV
- 13.2%
- B/E move
- 1.4%
- Pseudo strike
- 21.38
- IV
- 21.7%
- B/E move
- 2.8%
65Δ
- Pseudo strike
- 18.35
- IV
- 14.9%
- B/E move
- 1.4%
- Pseudo strike
- 21.77
- IV
- 22.2%
- B/E move
- 1.8%
70Δ
- Pseudo strike
- 18.11
- IV
- 16.5%
- B/E move
- 1.4%
- Pseudo strike
- 22.15
- IV
- 22.7%
- B/E move
- 0.9%
75Δ
- Pseudo strike
- 17.88
- IV
- 18.1%
- B/E move
- 1.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 17.65
- IV
- 19.8%
- B/E move
- 1.3%
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
SLS
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the…
More →SMMT
Description unavailable
More →SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
More →SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR)…
More →SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to…
More →SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic…
More →